Advertisement
Mr. Haggerty joins Mylan from Sanofi-Aventis U.S. Inc. where he served asVice President, General Counsel, and Corporate Secretary. He joinedSanofi-Aventis after serving as Vice President and General Counsel for U.S.Commercial Operations at Aventis Pharmaceuticals, which was acquired by Sanofiin 2004. Prior to joining Aventis, Mr. Haggerty served as Head of the ProductLiability Group at Warner-Lambert Company and, prior to that, he practiced fornine years at Shearman & Sterling LLP. Mr. Haggerty joins Mylan with 23 yearsof litigation, commercial, and regulatory experience, including 14 years inthe pharmaceutical sector.
Advertisement
Mylan Vice Chairman and CEO Robert J. Coury said: "In Joe, Mylan is addingyet another highly qualified, top-caliber individual to bolster our broad anddeep senior management team. His broad-based litigation experience, strongbackground in the pharmaceutical industry, and previous experience integratingtwo legal departments in a post-merger environment make him uniquely qualifiedfor this position at Mylan."
Mr. Haggerty said: "I am thrilled to be joining Mylan at this excitingtime in the Company's history. I look forward to joining the alreadyimpressive global management team and supporting them and their operationswith my counsel as Mylan becomes one of the leading quality generic andspecialty pharmaceutical companies in the world."
Mr. Haggerty earned a JD and a Bachelor of Arts degree from St. John'sUniversity.
Mylan Inc. is one of the world's leading quality generic and specialtypharmaceutical companies. The Company offers one of the industry's broadestand highest quality product portfolios, a robust product pipeline and a globalcommercial footprint through operations in more than 90 countries. Through itscontrolling interest in Matrix Laboratories Limited, Mylan has direct accessto one of the largest active pharmaceutical ingredient (API) manufacturers inthe world. Dey L.P., Mylan's fully integrated specialty business, provides theCompany with innovative and diversified opportunities in the respiratory andallergy therapeutic areas.For more information about Mylan, please visit www.mylan.com. CONTACT: Kris King 724-514-1800
SOURCE Mylan Inc.